TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17133785
Drug: Pioglitazone combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone combined with metformin (1500 mg/day increasing to 3000 mg/day)
Study: 17133785
Drug: Rosiglitazone combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosiglitazone combined with metformin (1500 mg/day increasing to 3000 mg/day)
Study: 10458359
Drug: Neoadjuvant hormonal
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Neoadjuvant hormonal therapy
Study: 9252771
Drug: Hydrocolloid +
Normalized name: psyllium hydrocolloid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocolloid + PVP-I treatment
Study: 9252771
Drug: Hydrocolloid treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocolloid treatment
Study: 8389339
Drug: High fat
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High fat meal (30 g margarine; 1327 kJ (317 kcal))
Study: 3040455
Drug: ACTH 4-10
Normalized name: ACTH
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ACTH 4-10 (0 mg)
Study: 3040455
Drug: ACTH 4-10
Normalized name: ACTH
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ACTH 4-10 (0.1 mg)
Study: 3040455
Drug: ACTH 4-10
Normalized name: ACTH
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ACTH 4-10 (1.0 mg)
Study: 3040455
Drug: ACTH 4-10
Normalized name: ACTH
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ACTH 4-10 (10 mg)
Study: 30003102
Drug: Electroacupuncture (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroacupuncture (EA) treatment for 36 sessions
Study: 26852398
Drug: UVB treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: UVB treatment (n=26)
Study: 26852398
Drug: Cholecalciferol injection
Normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholecalciferol injection (n=20)
Study: 24931748
Drug: Homeopathic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Homeopathic treatment plus usual care
Study: 19774349
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (50 mg daily)
Study: 28959158
Drug: Pre-workout supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-workout supplement (PWS) - Reckless™
Study: 23089176
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of pregabalin, cetirizine, and pheniramine maleate
Study: 23089176
Drug: Antihistaminic combination
Normalized name: Ahist Antihistamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihistaminic combination (cetirizine with pheniramine maleate)
Study: 21647425
Drug: Polypill (aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polypill (aspirin 75 mg, lisinopril 10 mg, hydrochlorothiazide 12.5 mg and simvastatin 20 mg)
Study: 19665601
Drug: lasofoxifene (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: lasofoxifene (0.25 mg/d)
Study: 9140673
Drug: Bunazosin (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bunazosin (6 and 12 mg once daily for 12 weeks)
Study: 9140673
Drug: Atenolol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (50 and 100 mg once daily for 12 weeks)
Study: 29423403
Drug: Amoxicillin +
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin + clavulanic acid (1 gr. tablet given 12 hours and 1 hour before surgery)
Study: 26699529
Drug: Cefepime (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefepime (50 mg/kg up to 2 g single dose perioperative intravenous infusion)
Study: 26699529
Drug: Ceftriaxone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone (50 mg/kg up to 2 g single dose perioperative intravenous infusion)
Study: 21214368
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (LLLT) (685 nm, energy density 10 J/cm(2)) in addition to conventional therapy
Study: 15620772
Drug: Chesterfield stent
Normalized name: castor fiber scent gland secretion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chesterfield stent for palatal endosseous implant placement
Study: 9797758
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose inhaled beclomethasone dipropionate (BDP) 500 micrograms three times daily for two months
Study: 9797758
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose inhaled beclomethasone dipropionate (BDP)
Study: 7544851
Drug: Consolidation Arm
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Consolidation Arm A: cytosine arabinoside 200 mg/m2 daily for 7 days and daunorubicin 45 mg/m2 daily for 3 days for three courses
Study: 7544851
Drug: Consolidation Arm
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Consolidation Arm B: one course as in Arm A followed by amsacrine 120 mg/m2 daily for 5 days and a 5-day continuous infusion of azacytidine 150 mg/m2/day
Study: 7544851
Drug: Consolidation Arm
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Consolidation Arm C: thioguanine and cytosine arabinoside 100 mg/m2 every 12 h and daunorubicin 10 mg/m2 daily for 5 days for three courses followed by four maintenance courses of cytosine arabinoside 100 mg/m2 daily for 5 days and daunorubicin 45 mg/m2 for 2 days every 13 weeks
Study: 7544851
Drug: Intensive consolidation
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive consolidation therapy with the same or different drugs used in induction
Study: 8448264
Drug: Insulin response
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin response
Study: 22845185
Drug: Subcutaneous Triptorelin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous Triptorelin acetate (0.1 mg/m(2), to a maximum of 0.1 mg)
Study: 22845185
Drug: Intravenous GnRH
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous GnRH 100 μg
Study: 18443672
Drug: Controlled-release (CR)
Normalized name: Afeditab CR
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Controlled-release (CR) tramadol 200 mg, titrated to a maximum of 400 mg per day
Study: 18443672
Drug: Sustained-release (SR)
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release (SR) diclofenac 75 mg, titrated to a maximum of 100 mg once daily or 75 mg twice a day
Study: 1571904
Drug: Hyperfractionated radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyperfractionated radiation therapy (HFX) with total doses of 6720, 7200, 7680, and 8160 cGy, using 120 cGy twice daily, 5 days per week.
Study: 1571904
Drug: Delays of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delays of 5 days or more in treatment.
Study: 6463064
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g cephradine
Study: 6463064
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg flucloxacillin plus 500 mg ampicillin
Study: 29582946
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose cannabis (6 patients)
Study: 29582946
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose cannabis (8 patients)
Study: 25016757
Drug: Narrowband UVB
Normalized name: zinc oxide
DrugBank: Zinc oxide (DB09321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Narrowband UVB therapy for 12 weeks
Study: 15831780
Drug: Cefpodoxime (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefpodoxime (400 mg)
Study: 9017772
Drug: Cefixime (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefixime (400 mg)
Study: 11572104
Drug: New cognitive-emotional
Approvals — FDA: no, EMA: no, PMDA: no
Description: New cognitive-emotional cognitive-behavioral therapy programmes (experimental group)
Study: 7703703
Drug: Alcohol and
Normalized name: Polyvinyl alcohol and povidone only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol and Behavioral Marital Therapy (ABMT)
Study: 7703703
Drug: Early treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early treatment dropouts
Study: 3477353
Drug: Special caries
Normalized name: Tilletia caries
DrugBank: Tilletia caries (DB10705)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Special caries preventive program with controlled antimicrobial treatment using Streptococcus mutans as an indicator organism.
Study: 31898212
Drug: Combination anti-depressants
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination anti-depressants
Study: 31898212
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of antipsychotics and anti-depressants
Study: 19061746
Drug: Telemedicine intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Telemedicine intervention (8 weekly sessions in the first 2 months, followed by biweekly sessions for 4 months)
Study: 16547994
Drug: Oral fluid
Normalized name: cascara sagrada ORAL FLUID EXTRACT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral fluid intake
Study: 7503000
Drug: Integrelin (dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrelin (dosing regimens: 180 and 135 micrograms/kg bolus, followed by 0.75 micrograms/kg/min infusion)
Study: 7503000
Drug: Integrelin (0.50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrelin (0.50 micrograms/kg/min infusion)
Study: 7503000
Drug: Integrelin with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrelin with aspirin and heparin
Study: 28288570
Drug: Tolvaptan 15,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolvaptan 15, 30 and 45 mg
Study: 21086279
Drug: Chlorhexidine/benzydamine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorhexidine/benzydamine plus paracetamol
Study: 21086279
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus paracetamol
Study: 14604457
Drug: Interferon-alpha therapy
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon-alpha therapy in patients who developed depression within the first 4 weeks
Study: 14604457
Drug: Interferon-alpha therapy
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon-alpha therapy in patients who developed depression later
Study: 14604457
Drug: Interferon-alpha therapy
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon-alpha therapy in patients with no psychiatric symptoms
Study: 9038464
Drug: Patient-controlled analgesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-controlled analgesia using morphine 1 mg bolus with a 10-min lockout and no background infusion
Study: 9038464
Drug: Intramuscular codeine
Normalized name: Codeine
DrugBank: Codeine (DB00318)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular codeine phosphate
Study: 6342841
Drug: Propranolol, 160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol, 160 mg/day
Study: 3993546
Drug: Atenolol, 100
Normalized name: Atenolol, 100 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol, 100 mg/day
Study: 31983653
Drug: CNIC polypill
Approvals — FDA: no, EMA: no, PMDA: no
Description: CNIC polypill (atorvastatin 40mg/ramipril 10mg/aspirin 100mg)
Study: 31983653
Drug: Atorvastatin (40mg)
Normalized name: atorvastatin 40 MG
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atorvastatin (40mg)
Study: 28033332
Drug: Direct Renin
Normalized name: DIRECT RENIN INHIBITOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct Renin Inhibitor (DRI) - Aliskiren
Study: 25006068
Drug: Zilpaterol hydrochloride
Normalized name: zilpaterol hydrochloride
DrugBank: Zilpaterol (DB11479)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zilpaterol hydrochloride (ZH; 8.3 mg/kg [100% DM basis]) for 20 d
Study: 25006068
Drug: Ractopamine hydrochloride
Normalized name: ractopamine hydrochloride
DrugBank: Ractopamine (DB11541)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ractopamine hydrochloride (RH; 30.1 mg/kg [100% DM basis]) for 28 d
Study: 25006068
Drug: Control diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control diet containing no β‐agonists
Study: 22865016
Drug: Combined behavioral
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined behavioral management and medication management intervention
Study: 12208438
Drug: Midazolam (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.1 mg/kg) + Thiopental (3 mg/kg)
Study: 1828191
Drug: Fluorodeoxyuridine (FUdR)
DrugBank: Floxuridine (DB00322)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluorodeoxyuridine (FUdR) at a dose of 0.3 mg/kg per day with oral leucovorin (LV) at a dose of 100 mg every hour for four doses before FUdR infusion and then every 4 hours during FUdR treatment.
Study: 1828191
Drug: Fluorodeoxyuridine (FUdR)
DrugBank: Floxuridine (DB00322)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluorodeoxyuridine (FUdR) at a dose of 0.25 mg/kg per day with oral leucovorin (LV).
Study: 1828191
Drug: Fluorodeoxyuridine (FUdR)
DrugBank: Floxuridine (DB00322)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluorodeoxyuridine (FUdR) at a dose of 0.375 mg/kg per day with oral leucovorin (LV).
Study: 7469003
Drug: Atosil (as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atosil (as a histamine blocker)
Study: 29242062
Drug: Intramuscular injections
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injections of allogeneic bone marrow-derived mesenchymal stromal cells (BM-MSCs) at a dosage of 5 × 10^6 MSCs per injection, 30 injections total.
Study: 29242062
Drug: Placebo injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injections (control group).
Study: 20395820
Drug: Intrathecal ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal ketorolac (0.5-2.0 mg)
Study: 20395820
Drug: Intrathecal ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal ketorolac (2.0 mg)
Study: 10759273
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg mifepristone followed by misoprostol 400 µg
Study: 10759273
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg mifepristone followed by misoprostol 400 µg
Study: 3103546
Drug: Fat emulsion
Normalized name: FAT EMULSION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fat emulsion administered at a constant rate over 24 hours, starting at 1 g/kg and increasing to a maximum of 4 g/kg
Study: 3103546
Drug: Fat emulsion
Normalized name: FAT EMULSION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fat emulsion administered at a constant rate over 16 hours, starting at 1 g/kg and increasing to a maximum of 4 g/kg
Study: 3103546
Drug: Fat emulsion
Normalized name: FAT EMULSION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fat emulsion administered at a constant rate of 4 g/kg a day over 24 hours
Study: 31594857
Drug: High-dose vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose vitamin D3 14,007 IU/d
Study: 28346912
Drug: VENT (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: VENT (no treatment)
Study: 26058417
Drug: 2 L/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 L/day of water for 30 days
Study: 23737079
Drug: CO2-laser treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: CO2-laser treatment (9.6 µm, pulse-duration 20 µs, pulse-repetition-rate 20 Hz, average fluence 4.5 ± 0.5 J/cm², 20 laser pulses per spot)
Study: 23737079
Drug: CO2-laser treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: CO2-laser treatment
Study: 21482568
Drug: Ceftaroline fosamil
Normalized name: Ceftaroline fosamil
DrugBank: Ceftaroline fosamil (DB06590)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ceftaroline fosamil (600 mg iv every 12 h)
Study: 21482568
Drug: Ceftriaxone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone (1 g iv every 24 h)
Study: 15154922
Drug: Two xylitol
Normalized name: Xylitol
DrugBank: Xylitol (DB11195)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Two xylitol tablets two times a day (1.7 g xylitol d(‐1)) for 18 weeks
Study: 15154922
Drug: Two xylitol
Normalized name: Xylitol
DrugBank: Xylitol (DB11195)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Two xylitol tablets four times per day (3.4 g xylitol d(‐1)) for 18 weeks
Study: 15154922
Drug: No tablets
Normalized name: caffeine Oral Tablet [No Doz]
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No tablets (Control Group)
Study: 9442992
Drug: Additional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Additional therapy (Control)
Study: 7686799
Drug: Terfenadine (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terfenadine (120 mg/day for 3 days)
Study: 30169600
Drug: Metformin (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (3 g/day after a dose-escalation period over 4 weeks)
Study: 18469257
Drug: Low zinc
Normalized name: insulin low zinc
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low zinc diets (<11 mg/d) for 4-8 weeks
Study: 31142242
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy of vitamin C, thiamine and hydrocortisone
Study: 25311423
Drug: Dexamethasone (short-term,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (short-term, high-dose, perioperative use)
Study: 21849187
Drug: Acute androgen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute androgen suppression therapy
Study: 21849187
Drug: Chronic androgen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chronic androgen suppression therapy
Study: 11441324
Drug: Zinc lozenges
Normalized name: Zinc Lozenges
DrugBank: Zinc gluconate (DB11248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zinc lozenges (four to six lozenges/day for 10 days)
Study: 2291748
Drug: Standardized garlic-powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized garlic-powder tablets (800 mg daily for 16 weeks)
Study: 2291748
Drug: Placebo tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets (same number as garlic tablets for 16 weeks)
Study: 28865799
Drug: Tedizolid phosphate
Normalized name: Tedizolid Phosphate
DrugBank: Tedizolid (DB14569)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tedizolid phosphate 400 mg PO
Study: 28865799
Drug: Tedizolid phosphate
Normalized name: Tedizolid Phosphate
DrugBank: Tedizolid (DB14569)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tedizolid phosphate 600 mg PO
Study: 28865799
Drug: Tedizolid phosphate
Normalized name: Tedizolid Phosphate
DrugBank: Tedizolid (DB14569)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tedizolid phosphate (all doses)
Study: 20979461
Drug: E2+DRSP (17β‐estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: E2+DRSP (17β‐estradiol 1 mg/day plus drospirenone 2 mg/day)
Study: 15019795
Drug: Fluoxetine (sub-analysis)
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluoxetine (sub-analysis)
Study: 8001289
Drug: Monoclonal antibody-based
Normalized name: SARS-CoV-2 antibody-based IVIG
DrugBank: Anti-SARS-CoV-2 immunoglobulin (DB16360)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monoclonal antibody-based enzyme immunoassay (EIA) for urinary 18-hydroxycortisol
Study: 3078281
Drug: Oral trifluoperazine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral trifluoperazine (TFP) 7 mg
Study: 3078281
Drug: Inhaled trifluoperazine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled trifluoperazine (TFP) 10 mg/ml, nebulized for 5 min
Study: 3078281
Drug: Saline (control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline (control for inhaled TFP)
Study: 28262330
Drug: Paracetamol prophylaxis
Normalized name: STONE PROPHYLAXIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol prophylaxis
Study: 19142041
Drug: Sham kinesiology
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham kinesiology treatment (administered weekly for 5 weeks)
Study: 19142041
Drug: Real kinesiology
Approvals — FDA: no, EMA: no, PMDA: no
Description: Real kinesiology treatment (4 sessions)
Study: 19142041
Drug: Sham kinesiology
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham kinesiology treatment (4 sessions)
Study: 16324923
Drug: glyburide (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: glyburide (10 mg)
Study: 16324923
Drug: glimepiride (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: glimepiride (4 mg)
Study: 11081528
Drug: Inhaled nitric
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitric oxide (n=63)
Study: 8885811
Drug: Specific IgE
Normalized name: BSA specific IgE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific IgE antibodies to food allergens (egg white, fish, wheat, peanut, soy, milk)
Study: 8885811
Drug: Specific IgE
Normalized name: BSA specific IgE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific IgE antibodies to food allergens
Study: 1525984
Drug: Tablets containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets containing 90% USRDA of Mg
Study: 1525984
Drug: Tablets containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets containing 180% USRDA of Mg
Study: 4091884
Drug: Ticlopidine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticlopidine treatment (500 mg/day) for 30 days
Study: 30682576
Drug: Mindset that
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindset that non-life-threatening symptoms are unfortunate side effects of treatment
Study: 25270426
Drug: U.S. Food
Approvals — FDA: no, EMA: no, PMDA: no
Description: U.S. Food and Drug Administration recommended pharmacologic treatments (RPT)
Study: 22828681
Drug: Caudal epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal epidural injections of 0.5% lidocaine mixed with 1 mL of steroid